Embryonal neoplasms of the central nervous system (CNS) represent nearly one-third of brain tumors in children aged <3 years.1,2 Medulloblastoma with its different histologic variants belongs to this group, representing up to 20% of pediatric CNS tumors. Cerebellar neuroblastoma is an extremely uncommon entity of this group with few published reports on primary cerebellar neuroblastoma.3,4 A number of second neoplasms have been reported in patients with neuroblastoma, including CNS tumors (gliomas and meningioma), but no prior reports of medulloblastoma. These second primary cancers have mostly occurred many years after long-term surveillance.5–7 This report presents a case of medulloblastoma in a child 5 months after successful treatment of stage IV neuroblastoma, and discusses the findings in the DNA sequencing results of both the resected posterior fossa tumor and the germline mutations.
The genetic analysis presented in this case reported was supported by the Khalifa Foundation and The Institute for Personalized Cancer Therapy (IPCT-MDACC). The patient was enrolled in the IPCT Clearing House protocol led by Dr. Funda Meric-Bernstam.
The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
See JNCCN.org for supplemental online content.
Louis DN, Perry A, Reifenberger G et al.. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–820.
Ostrom QT, Gittleman H, Farah P et al.. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013;15(Suppl 2):ii1–56.
Yagishita S, Itoh Y, Chiba Y et al.. Cerebellar neuroblastoma. A light and ultrastructural study. Acta Neuropathol 1980;50:139–142.
Applebaum MA, Henderson TO, Lee SM et al.. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer 2015;62:128–133.
Applebaum MA, Vaksman Z, Lee SM et al.. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2017;72:177–185.
Huibregtse KE, Vo KT, DuBois SG et al.. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer 2016;66:144–152.
Chen K, Meric-Bernstam F, Zhao H et al.. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem 2015;61:544–553.
DePristo MA, Banks E, Poplin R et al.. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491–498.
Zhou W, Chen T, Zhao H et al.. Bias from removing read duplication in ultra-deep sequencing experiments. Bioinformatics 2014;30:1073–1080.
Lonigro RJ, Grasso CS, Robinson DR et al.. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 2011;13:1019–1025.
Bamford S, Dawson E, Forbes S et al.. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355–358.
McLaren W, Pritchard B, Rios D et al.. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 2010;26:2069–2070.
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
Mao Y, Chen H, Liang H et al.. CanDrA: cancer-specific driver missense mutation annotation with optimized features. PLoS One 2013;8:e77945.
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073–1081.
Kato K, Ijiri R, Tanaka Y et al.., Metachronous renal cell carcinoma in a child cured of neuroblastoma. Med Pediatr Oncol 1999;33:432–433.
Tanaka M, Kato K, Gomi K et al.. Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma. Am J Surg Pathol 2009;33:1416–1420.
Krieger JN, Chasko SB, Keuhnelian JG. Paratesticular neuroblastoma associated with subependymal giant cell astrocytoma. J Urol 1980;124:736–738.
Jongmans MC, Loeffen JL, Waanders E et al.. Recognition of genetic predisposition in pediatric cancer patients: an easy-to-use selection tool. Eur J Med Genet 2016;59:116–125.
Thomas M, Enciso V, Stratton R et al.. Metastatic medulloblastoma in an adolescent with Simpson-Golabi-Behmel syndrome. Am J Med Genet A 2012;158A:2534–2536.
Huynh H, Hao HX, Chan SL et al.. Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus. Mol Cancer Ther 2015;14:1224–1235.
Takita J, Yang HW, Chen YY et al.. Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene 2001;20:4424–4432.
Piao Z, Lee KS, Kim H et al.. Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer 2001;30:113–122.
Narayan G, Pulido HA, Koul S et al.. Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 2003;22:3489–3499.
Rube CE, Fricke A, Schneider R et al.. DNA repair alterations in children with pediatric malignancies: novel opportunities to identify patients at risk for high-grade toxicities. Int J Radiat Oncol Biol Phys 2010;78:359–369.
Falk RE, Casas KA. Chromosome 2q37 deletion: clinical and molecular aspects. Am J Med Genet C Semin Med Genet 2007;145C:357–371.
Sijmons RH, Hofstra RM. Review: clinical aspects of hereditary DNA mismatch repair gene mutations. DNA Repair (Amst) 2016;38:155–162.
Lindsay H, Jubran RF, Wang L et al.. Simultaneous colonic adenocarcinoma and medulloblastoma in a 12-year-old with biallelic deletions in PMS2. J Pediatr 2013;163:601–603.
Scott RH, Mansour S, Pritchard-Jones K et al.. Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol 2007;4:130–134.
Privalsky ML. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 2004;66:315–360.
Pugh TJ, Weeraratne SD, Archer TC et al.. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012;488:106–110.
Rebouissou S, Vasiliu V, Thomas C et al.. Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet 2005;14:603–614.
Kelleher FC, O'Sullivan H, Smyth E et al.. Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis 2013;34:2198–2205.
Sturla LM, Merrick AE, Burchill SA. FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells. Br J Cancer 2003;89:1276–1284.
Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005;23:6285–6295.
Eggert A, Ikegaki N, Kwiatkowski J et al.. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000;6:1900–1908.
Huber H, Eggert A, Janss AJ et al.. Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer 2001;37:2064–2072.
van Nes J, Chan A, van Groningen T et al.. A NOTCH3 transcriptional module induces cell motility in neuroblastoma. Clin Cancer Res 2013;19:3485–3494.
Cohen BH, Geyer JR, Miller DC et al.. Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. A report from the Children's Oncology Group. Pediatr Neurol 2015;53:31–46.
- Search Google Scholar
- Export Citation
. Cohen BH Geyer JR Miller DC Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. A report from the Children's Oncology Group. Pediatr Neurol 2015; 53: 31– 46.
Pihlak R, Valle JW, McNamara MG. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget 2017;8:73240–73257.
Viale G, Trapani D, Curigliano G. Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. Biomed Res Int 2017;2017:4719194.